Vitamin B12 —biodegradable micro particulate conjugate carrier systems for peroral delivery of drugs, therapeutic peptides/proteins and vaccines

• US 6,482,413 B1
• Filed: 03/01/2001
• Issued: 11/19/2002
• Est. Priority Date: 02/26/2001
• Status: Expired due to Fees

• Current Assignee: Council of Scientific & Industrial Research
• Original Assignee: Council of Scientific & Industrial Research
• Inventors: Chalasani, Kishore Babu, Rao, Kollipara Koteshawar, Russell-Jones, Gregory John, Diwan, Vamanrao, Jain, Sanjain Kumar, Raghavan, Kondapuram Vijaya
• Primary Examiner(s): Park, Hankyel T.
• Application Number:
  US09/795,979
• Publication Number:
  US 20020192235A1
• Time in Patent Office: 628 Days
• Field of Search: 424/194.1, 514/52
• US Class Current: 424/194.1
• CPC Class Codes: A61K 47/54 the modifying agent being an organic compound
• CPC Class Codes: A61K 9/1635 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• CPC Class Codes: A61K 9/1641 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
• CPC Class Codes: A61K 9/1652 Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin homeopathic globules A61K9/1623
• CPC Class Codes: A61K 9/167 with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface with further drug-free outer coating A61K9/5073
• CPC Class Codes: A61K 9/5026 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• CPC Class Codes: A61K 9/5031 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
• CPC Class Codes: A61K 9/5036 Polysaccharides, e.g. gums, alginate; Cyclodextrin
• CPC Class Codes: A61K 9/5153 Polyesters, e.g. poly(lactide-co-glycolide)
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
• CPC Class Codes: Y10S 977/906 Drug delivery

Abstract

The invention relates to a novel complex for oral delivery of drugs, therapeutic protein/peptides and vaccines which are loaded in a Vitamin B₁₂ (VB₁₂) coupled particulate carrier system with spacers in between, the carrier system with spacers having a formula VB₁₂—R′/R″—N wherein, R′ or R″ is spacer and/or agents for derivatization of VB₁₂ to provide either NH₂ or COOH or SH groups, and N is the micro or nano particle carriers for the delivery of injectable drugs, therapeutic protein/peptides and vaccines.

Claims

1. A complex for oral delivery of drugs, therapeutic proteins and peptides, and vaccines, which are loaded in a Vitamin B₁₂ (VB₁₂) coupled particulate carrier system having one or more spacers in between, and having the formula VB₁₂—

R′

/R″

—

N, wherein each of R′ and

R″

is a spacer for the derivative of said VB₁₂ to provide NH₂, COOH, or SH group;

N is a micro or nano particle carrier for the delivery of injectable drugs, therapeutic proteins and peptides, and vaccines; and

said VB₁₂ retains its intrinsic factor (IF) affinity after coupling to said carrier through said spacer.

2. A complex as claimed in claim 1, wherein said drugs, therapeutic proteins and peptides, and vaccines are selected from the group consisting of drugs, therapeutic proteins and peptides, and vaccines heretofore administered exclusively by parenteral routes.

3. A complex as claimed in claim 1, wherein said drug is gentamycin or amikacin.

4. A complex as claimed in claim 1, wherein said carrier system is a biodegradable polymeric particulate carrier.

5. A complex as claimed in claim 1, wherein said VB₁₂ is a native cyanocobalamin (VB₁₂) or its analog selected from the group consisting of:

aquocobalamin, adenosylcobalamin, methylcobalamin, hydroxycobalamin and their derivatives,

alkylcobalamine in which alkyl chain is linked to cobalt of a VB₁₂,

cyanocobolamine with chloro, sulphate, nitro, thio or its analide, ethylamide propionamide,

monocarboxylic and dicarboxylic acid derivatives of a VB₁₂ or its analog,

monocarboxylic, dicarboxylic and tricarboxylic acid derivatives and prominamide derivatives of ‘

e’

isomer of monocarboxy VB₁₂, and

analogues of VB₁₂ in which cobalt is replaced by other metals.

6. A complex as claimed in claim 1, wherein said one or more spacers link the primary 5′

-hydroxyl and/or 2′

-hydroxyl of the ribose moiety of the derivative of VB₁₂ to said particulate carrier.

7. A complex as claimed in claim 1, wherein said spacer is the residue after linking of a compound selected from the group consisting of diacids (COOH—

COOH), alkyl diacids (COO(CH₂)nCOO)), alkyl diamines (NH₂(CH₂)n—

NH₂), alkyl diamides (NHCO (CH)nCONH₂), hydrazides (NH₂NH₂), alkyl dihydrazides (NH₂NHCO(CH₂)nCONHNH₂, SH group containing agents (N-succinymidyl₃-(2-pyridyidithio), propionate or its long chain alkyl derivatives or acid anhydrides [(CH)nCOCOO)], acid halide spacers (R(CH₂)nCOCl), and anhydroxy activated ester functional groups (NHS) which are used for the peptide bonds or surfactant derivatives or polymeric spacers.

8. A complex as claimed in claim 1 wherein, the microspheres or nanoparticles are made up of biodegradable and pharmaceutically acceptable polymers.

9. A complex as claimed in claim 1 wherein, the drug loaded polymeric particulates degrade in-vivo to release and deliver a protein pharmaceutical/vaccine for its bioactive response.

10. A complex as claimed in claim 1, wherein said particulate carrier is a biodegradable hydrophobic or hydrophilic polymeric microsphere or nanoparticle having one or more functional groups selected from the group consisting of COOH, anhydride, NH₂ and SH groups on its surface which are used for linkage to said spacer.

11. A complex as claimed in claim 1, wherein said particulate carrier is a monolithic particle, reservoir particle, multi particulate particle, or conjugate polymer particle.

12. A complex as claimed in claim 1, wherein said particulate carrier comprises a polysaccharide polymer selected from the group consisting of starch and its derivatives, pectin, amylose, guar gum and its derivatives, dextran and its derivatives, chitosan and its derivatives, chondroitin sulphate and its derivatives, and the natural and semi-synthetic derivatives of polysaccharides.

13. A complex as claimed in claim 12, wherein said polysaccharide is crosslinked with an agent selected from the group consisting of epichlorohydrin, POCl₃, borax, and aldehydes.

14. A complex as claimed in claim 10, wherein said biodegradable polymer is selected from the group consisting of poly(methylmethacrylate), poly(hydroxybutyrate), polylactide(coglycolic acid), poly(anhydride) microspheres of (fumaric acid:

sebacic acid), poly (fumaric acid), poly (lactide co-glycolide), fatty acylated particulates, LDL carriers, and multiparticulate systems.

15. A complex as claimed in claim 1, wherein said particulate carrier further comprises a natural protein polymer selected from the group consisting of albumin, gelatin, a semi synthetic or peptide based synthetic polymer and their derivatives.

16. A complex as claimed in claim 1, wherein the size of said complex ranges from about a few nanometers to about 10 μ

m.

17. A complex as claimed in claim 1 wherein, these particulate systems which are modified or activated on the surface to suit VB₁₂ linkage and/or complexation.

18. A complex as claimed in claim 16 wherein, the particulate system is surface modified with VB₁₂ and includes coupling of VB₁₂ to biodegradable particulate carriers.

19. A complex as claimed in claim 16, wherein, coupling of VB₁₂ derivative and particulates include both biodegradable and non biodegradable bonds with and without spacers in between.

20. A complex as claimed in claim 1, wherein said VB₁₂ derivative and said particulate carrier are coupled by amide bond of a carbodiimide selected from the group consisting of 1-ethyl 3-3dimethyl amino propyl carbodiimide (EDAC), 1,1′

carbonyl diimidazole (CDl), N,N′

diisopropyl carbodiimide (DIPC), and other peptide coupling agents or N-hydroxy succinimide activated coupling (NHS) or periodate coupling or glutaraldehyde activated coupling or CNBR mediated coupling or acid halide induced amide coupling or by the use of hydrophilic spacer ethylene glycol bis (succinimidyl succinate) (EGS) or hydrophobic spacers disuccinimidyl suberate (DSS) or via a thiol cleavablespacer with N-succinimidyl 3-(2-pyridyidithio) propionate (SPDP).

21. A complex as claimed in claim 1 wherein, the coupling involves physical adsorptive type or complexation.

22. A complex as claimed in claim 1, wherein said drugs, therapeutic peptides and proteins, or vaccines are entrapped within the highly dense VB12 coupled biodegradable particulate carriers.

23. A complex as claimed in claim 1, wherein the loading step of said drugs, therapeutic proteins and peptides, and vaccines to said carrier is preformed during the preparation of said particle carrier, or during the coupling process between said particle carrier and said VB₁₂ derivative.

24. A complex as claimed in claim 22, wherein said drugs, therapeutic peptides and proteins, or vaccines are entrapped within said carrier before, after, or during the process of conjugation, adsorption, covalent coupling, ionic interaction or complexation between said carrier and said VB₁₂.

25. A complex as claimed in claim 1, wherein a surfactant, an aggregation minimizer, a protease inhibitor, or a permeation enhancer is added as an additive into said system.

26. A complex as claimed in claim 1, wherein said delivery system is co-administered with an exogenous intrinsic factor (IF) of VB₁₂.

27. A complex as claimed in claim 1, wherein said delivery system is formulated into a dosage form suitable for oral delivery.

28. A complex as claimed in claim 27, wherein said oral dosage form is solution, suspension, gel, paste, elixir, viscous colloidal dispersion, tablet, capsule, or oral control release type.

29. A complex as claimed in claim 1, wherein said therapeutic peptides and proteins are selected from the group consisting of insulin, EPO, G-CSF, GM-CSF, Factor VIII, LHRH analogues and Interferons.

30. A complex as claimed in claim 1, wherein, said vaccines are selected from the group consisting of Hepatitis ‘

B’

surface antigen vaccine, typhoid vaccine and cholera vaccine.

31. A method of modifying a micro or nano particle carrier for delivery of injectable drugs, therapeutic proteins and peptides, or vaccines to make it suitable for oral delivery, the method comprising coupling to said carrier a Vitamin B₁₂ to form a complex as claimed in claim 1.